彌漫大B細(xì)胞淋巴瘤患者血清白細(xì)胞介素17及白細(xì)胞介素35的表達(dá)及臨床意義

打開文本圖片集

Expressionand clinical significance of IL-17and IL-35 in patients with diffuse large B-cellymphoma LinYuanfeng'，WenXiaofangl，LiuHuimei'，F(xiàn)angXiaoli'，HuangYiqun 'Departmentof ClinicalLaboratory，ZhangzhouHospitalAfliatedtoFujian Medical University，Zhangzhou363000，

China;2DepartmentofHematology，Zhangzhou HospitalAfiliatedtoFujianMedicalUniversity，Zhangzhou363000， China

【Abstract】ObjectiveTo explore thecorrelation between thechanges of serum IL-17and IL-35 levels in patients with DLBCL and the development，clinical data，treatmentplan and therapeutic effect of DLBCL，so as to provideanew theoretical basis for the diagnosis，treatment and prognosisassessment of DLBCL.Methods Screening a total of 62 patientswith DLBCL diagnosed bypathological and immunohistochemical examinations in theZhangzhouHospitalafiliatedofFujianMedicalUniversityfromJanuary2O21toJanuary2O24 wereincludedin the study group.40 healthy volunteers from the same period were selected as thecontrol group.The expressionlevels of IL-17and IL-35 were detected byELISA.ResultsThe serum IL-17levelof DLBCL patients was lower than thatof control group，but IL-35level was higherthanthatof thecontrol group.Serum levelsofIL-17and IL-35 in DLBCL patients werecorrelated with the Ann-Arbor stages，IL-17 was negatively corelated with the stage（r=-0.79， （204 P <0.05），but IL-35 was positively（r=0.71， P<0.05 ）. After treatment with RCHOP and CHOP in DLBCL patients，the increase of IL-17 and the decrease of IL-35 in RCHOP group were more significant than those in CHOP group. ConclusionThere are abnormal IL-17and IL-35 levels in DLBCL patients.RCHOP is more effctive than CHOP in increasing IL-17anddecreasing IL-35levels inserumof DLBCL patients.ThelevelsofIL-17andIL-35inserum of DLBCL patientsarecorrelatedwiththeprognosis.ThehigherlevelofIL-17andthelowerlevelofIL-35，thebetter prognosis of DLBCL patients.

【Key words】 Diffuse large B-cell lymphoma; Interleukin-17; Interleukin-35

DOI：10.19522/j.cnki.1671-5098.2025.05.016

淋巴瘤作為一組起源于淋巴結(jié)或其余淋巴組織的惡性腫瘤，根據(jù)組織病理學(xué)特征和臨床特點分為霍奇金淋巴瘤（Hodgkin'slymphoma，HL）和非霍奇金淋巴瘤（non-Hodgkinlymphoma，NHL）。（剩余8993字）